Management of the patient with severe refractory rheumatoid arthritis: Are the newer treatment options worth considering?

BioDrugs

Volumn 13, Issue 6, 2000, Pages 425-435

  Lacki, Jan K ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CPH 82; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AUTOIMMUNITY; DISEASE SEVERITY; DRUG EFFECT; GENE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TARGET CELL; VACCINATION;

EID: 0033911285     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013060-00006     Document Type: Review

References (136)

1. 1. Pincus T. Rheumatoid arthritis: a medical emergency? Scand J Rheumatol 1994; 23: 21-30
2. 2. Vandenbroucke IP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol 1984; 11: 158-61
3. 3. Kvalvik AG, Jones MA, Symmons DPM. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29: 29-37
4. 4. Gilliand BC. Rheumatoid arthritis: a model of chronic inflammation. In: Wolf HP, Fleckenstein A, Philipp E, editors. Drug research in the 21st century. New York (NY): Springer, 1995: 43-50
5. 5. Liang MH. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 522-9
6. 6. Pincus T. Clinical observations often provide more accurate information concerning the long-term natural history and results than structured research studies. Rheumatol Eur 1995 ; 2 Suppl.: 179-84
7. 7. Boers M, Tugwell P, Felstone DT, et al. WHO and IL-R core end points for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 21: 86-9
8. 8. Weinblatt ME. The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology (Oxf) 1999; 38 Suppl. 2: 19-23
9. 9. Janossy G, Duke O, Poulter LW, et al. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 1981; II: 839-42
10. 10. Kavanaugh A. Antiadhesion therapy in rheumatoid arthritis. Bio-Drugs 1997; 7 (2): 119-33
11. 11. Allavena P, Piemonti L, Longoni D. IL 10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359-69
12. 12. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51: 919-25
13. 13. Girard J-P, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 1995; 16:449-57
14. 14. Yanni G, Whelan A, Feighery C, et al. Morphometric analysis of synovial membrane blood vessels in rheumatoid arthritis: association with the immunohistologic features, synovial fluid cytokine levels and clinical course. J Rheumatol 1993; 20: 634-8
15. 15. Ziff M. Role of the endothelium in chronic inflammatory synovitis. Arthritis Rheum 1991; 34: 1345-52
16. 16. Chikanza IC, Jawed S, Naughton D, et al. Why do we need new treatments for rheumatoid arthritis? J Pharm Pharmacol 1998; 50: 357-69
17. 17. Murray KM, Dahl SL. Recombinant human tumor necrosis factor (p75) Fc fusion protein (TNFR: Fc) in rheumatoid arthritis. Ann Pharmacother 1997; 31: 1335-8
18. 18. Ahmadzadeb N, Shingu M, Nobunaga M. The effect of recombinant tumor necrosis factor-alpha on Superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990; 8: 387-91
19. 19. Baert F, Peeters M, D'Haens G, et al. Impressive histologic improvement after TNF antibody (cA2) therapy in active Crohn's disease [abstract]. Gut 1996; 39 Suppl. 1: A17
20. 20. MacNaul KL, Chartrain N, Lark M, et al. Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and then natural inhibitor, TIMP, in rheumatoid synovial fibroblasts. Matrix 1992; 1 Suppl.: 198-9
21. 21. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993; 94: 145-9
22. 22. Taylor PC, Chapman P, Elliott MJ, et al. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNFα therapy [abstract]. Arthritis Rheum 1997; 40 Suppl.: S80
23. 23. Moreland LW. Recent advances in anti-tumour necrosis factor (TNF) therapy in rheumatoid arthritis. BioDrugs 1999; 11 (3): 201-10
24. 24. Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 1998; 10 (5): 397-422
25. 25. Rau R, Simianer S, Weier R, et al. Effective combination of the fully human anti-TNF antibody D2E7 and methotrexate in active rheumatoid arthritis [abstract no. 907]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
26. 26. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 1995; 7 (3): 251-9
27. 27. Siegel SA, Shealy DJ, Nakada MT. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vitro. Cytokine 1995; 7(1): 15-25
28. 28. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30 (16): 1443-53
29. 29. Elliott MJ, Maini RN, Feldman M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7
30. 30. Kavanaugh AF, Cush JJ, St Clair EW, et al. Anti-TNFα monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): results of double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996 Sep; 39 Suppl.: 123
31. 31. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41 (9): 1552-63
32. 32. Antoni C, Maini R, Breedveld F, et al. Subgroup analyses show consistent clinical benefit in a 30-week double blind trial (attract) with an anti-TNFα monoclonal antibody, infliximab, in rheumatoid arthritis patients on methotrexate [abstract no. 905]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
33. 33. Maini RN, Smolen J, Breedveld F, et al. Anti-TNFα monoclonal antibody, infliximab (cA2, remicade™), in active rheumatoid arthritis combined with methotrexate therapy: results of a phase III trial at 30 weeks [abstract no. OP9]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
34. 34. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-9
35. 35. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431-45
36. 36. Brockhaus M, Schoenfeld HJ, Schlager EJ, et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87:3127-31
37. 37. Chikanza IC, Roux Lombard P, Dayer JM, et al. Tumor necrosis factor soluble receptors behave as acute phase reactants following surgery on patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993; 92: 19-22
38. 38. Roux Lombard P, Punze L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-9
39. 39. Cooksey LJ. A TNF-receptor blocker for treating patients with refractory rheumatoid arthritis. Formulary 1999; 34: 211-9
40. 40. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Therapeutics 1999; 21 (1): 75-87
41. 41. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86
42. 42. Roøgind H, Qvistgaard E, Graff LB, et al. Ultrasonographic changes in relation to clinical observations after treatment of rheumatoid arthritis (RA) with Enbrel® (TNF-α receptors, TNR) [abstract no. 410]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
43. 43. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340 (4): 253-9
44. 44. Weinblatt ME. Long term and phase III treatment of DMARD-failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR: Fc; Enbrel) [abstract no. 572]. American College of Rheumatology 61st National Scientific Meeting; 1997 Nov 9; Washington, DC
45. 45. Jorgensen C, Apparailly F, Sany J. Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what we have learnt? Ann Rheum Dis 1999; 58: 136-41
46. 46. Besedovsky H, del Roy A, Sorkin E, et al. Immunoregulatory feedback between Il-1 and the glucocorticoid hormones. Science 1986; 233: 652-66
47. 47. Drevlow BE, Lovis R, Haag MA, et al. Recombinant human interleukin-1 receptor type 1 in the treatment of patients with active RA. Arthritis Rheum 1996; 39: 257-65
48. 48. Lebsack ME, Paul CC, Bloedow DC, et al. Subcutaneous IL-1 receptor antagonists in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1991; 34 Suppl.: 45
49. 49. Lebsack ME, Paul CC, Martindale JJ, et al. A dose-and regimenranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1993; 36 Suppl.: 39
50. 50. Lorenz HM, Kalden JR. Biological agents in rheumatoid arthritis. BioDrugs 1998; 9: 303-24
51. 51. Bresnihan B, Lookabaugh J, Witt K, et al. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996; 39 Suppl.: 73
52. 52. Campion GV, Lebsack ME, Lookabaugh J, et al. IL-1RA Arthritis Study Group. Dose range and dose frequency study of recombinant human IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1092-101
53. 53. Watt I, Cobby M. Recombinant human IL-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl.: 123
54. 54. Isomaki P, Luukkanes R, Saario R, et al. Interleukin-10 functions as an anti inflammatory cytokine in rheumatoid arthritis. Arthritis Rheum 1996; 39: 386-95
55. 55. Breedveld FC. Future trends in the treatment of rheumatoid arthritis: cytokine targets. Rheumatology (Oxf) 1999; 38 Suppl. 2: 11-3
56. 56. Koopman WJ, Gay S. Do nonimmunologically mediated pathways play a role in the pathogenesis of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19: 107-22
57. 57. Moreland LW, Koopman WJ. Biologic agents as potential therapies for treatment of autoimmune disease. In: Koopman WJ, editor. Arthritis and allied conditions. 13th ed. Baltimore (MD): Williams and Wilkins, 1997: 777-809
58. 58. Lapadula G, Iannone F, Zuccaro C, et al. Recovery of erosive rheumatoid arthritis after human immunodeficiency virus-1 infection and hemiplegia. J Rheumatol 1997; 24 (4): 747-51
59. 59. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 1992; 10: 519-60
60. 60. Yocum DE. Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 1996; 22: 133-54
61. 61. Moris RE. Rapamycin: FK-506's fraternal twin or distant cousin? Immunol Today 1991; 12: 137-40
62. 62. Kay JE, Kromwel L, Doe SEA, et al. Inhibition of T and B lymphocytes proliferation by rapamycin. Immunology 1991 ; 72: 544-9
63. 63. Lin CS, Boltz RC, Siekierka JJ, et al. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol 1991; 133: 269-84
64. 64. Hermann B, Meuller W. Die therapie der chronischen polyarthritis mit cyclosporin A, einens neuen immun-suppressivum. Aktuel Rheumatol 1979; 4: 173-86
65. 65. Kim Wu, Cho ML, Kim SI, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe refractory rheumatoid arthritis. J Rheumatol 2000; 27: 324-31
66. 66. Pasero G, Ferraccioli GF, Portioli I. Risks and benefit of low-dosage cyclosporin in rheumatoid arthritis. BioDrugs 1997; 7: 376-85
67. 67. Arita C, Hotokebuchi T, Miyahara H, et al. Inhibition by FK-506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol 1990; 82: 456-61
68. 68. Carlson RP, Hartman DA, Tomchek LA, et al. Rapamycin, a potential disease-modifying antiarthritic drag. J Pharmacol Exp Ther 1993; 266: 1125-38
69. 69. Miyahara H, Hotokebachi T, Arita C, et al. Comparative studies of the effects of FK-506 and Cyclosporine A on passively transferred collagen-induced arthritis in rats. Clin Immunol Immunopathol 1991; 60: 278-88
70. 70. Gremillion RB, Posever JO, Manek N, et al. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol 1999; 26: 2332-6
71. 71. Plosker GL, Wagstaff AJ. Leflunomide. Clin Immunother 1996; 6 (4): 300-5
72. 72. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-50
73. 73. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind randomised, multicentre trial. Lancet 1999; 353: 259-66
74. 74. Emery P, Breedveld F, Lemmel EM, et al. A phase III, randomized, double-blind study of leflunomide versus methotrexate in rheumatoid arthritis [abstract no. 399]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
75. 75. Furst D, Weaver A, Strand V. A comparison of leflunomide, placebo, and methotrexate for the treatment of active rheumatoid arthritis [abstract no. 398]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
76. 76. Kalden JR, Smolen JS, Rozman B. Leflunomide vs placebo vs sulfasalazine in rheumatoid arthritis: impact on functional ability [abstract no. 887]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
77. 77. Larsen A, Emery P, Loew-Friedrich I, et al. Comparison of radiographie endpoints in rheumatoid arthritis patients treated with leflunomide or methotrexate [abstract no. 86]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11 ; Glasgow
78. 78. Schiff M, Kaine J, Sharp J, et al. Retardation of radiographie disease progression in active rheumatoid arthritis with leflunomide compared to placebo and methotrexate [abstract no. 886]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
79. 79. Euqui EM, Almquist SJ, Muller CS et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxy guanosine nucleotide depletion. Scand J Immunol 1991; 33: 1616-73
80. 80. Schiff MH, Goldmlum R, Rees MMC. New DMARD, mycophenolate mofetil, effectively treats refractory rheumatoid arthritis patients for one year [abstract]. Arthritis Rheum 1991; 34 Suppl.: 89
81. 81. Larsen A, Petersson I, Svensson B. Podophyllum derivatives (CPH 82) compared with placebo in treatment of rheumatoid arthritis. Br J Rheumatol 1989; 28: 124-7
82. 82. Bjoørneboe O, Moen F, Nygaard H, et al. CPH-82 (Reumacon®) versus auranofin (Ridaura®): a 36-week study of their respective onset of action rates in RA. Scand J Rheumatol 1998; 27: 26-31
83. 83. Gudmundsdüttir E, Jünsson H. Reumacon (CPH 82) in refractory inflammatory arthritis [abstract no. 889]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
84. 84. Petersson I, Hedin P-J. Treatment of rheumatoid arthritis with reumacon: a placebo double-blind controlled study [abstract]. Scand J Rheumatol 1990; 19 Suppl. 85: 48
85. 85. Korpela M, Tiitinen S, Nissilä M. CPH 82 versus azathioprine in the treatment of rheumatoid arthritis and reactive (AA) amyloidosis [abstract no. 888]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
86. 86. Evans CH, Robbins PD, Ghivizzani SD, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-80
87. 87. Evans CH, Whalen JD, Ghivizzani SC, et al. Gene therapy in autoimmune diseases. Ann Rheum Dis 1998; 57: 125-7
88. 88. Boyle DL, Nguyen KH, Zhuang S, et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2 activity. Gene Ther 1999; 6: 1911-8
89. 89. Evans CH, Robbins PD. Gene therapy of arthritis. Intern Med 1999 Mar; 38: 233-9
90. 90. MacCarthy M. Gene therapy for rheumatoid arthritis starts clinical trials. Lancet 1996; 348: 323
91. 91. Moreland LW, Koopman WJ. Vaccination against rheumatoid arthritis: concepts and progress. BioDrugs 1997; 8 (2): 87-95
92. 92. Gustafsson K, Karlsson M, Anderson L, et al. Structures on the I-A molecule predisposing to susceptibility to type II collagen-induced autoimmune arthritis. Eur J Immunol 1990; 20: 2127-31
93. 93. Lider O, Karin N, Shinitsky M, et al. Therapeutic vaccination against adjuvant arthritis using autoimmune T-cells treated with hydrostatic pressure. Proc Natl Acad Sci USA 1987; 84: 4577-80
94. 94. Lohse AW, Bakker NPM, Hermann E, et al. Induction of an anti-vaccine response by T-cell vaccination in non-human primates and humans. J Autoimmun 1993; 1 (1): 121-30
95. 95. Mor F, Lohse AW, Karin N, et al. Clinical modeling of T-cell vaccination against autoimmune disease in rats: selection of antigen-specific T-cells using a mitogen. J Clin Invest 1990; 85: 1594-8
96. 96. Moreland LW, Heck Jr LW, Koopman WJ, et al. Vβ17 T-cell receptor peptide vaccine: results of phase I dose-finding study in patients with rheumatoid arthritis. Ann N Y Acad Sci 1995; 756:211-4
97. 97. Prakken B, Samodal R, Bonnin D, et al. Immunomodulatory effects of treatment with a 'shared epitope' peptide in patients with rheumatoid arthritis [abstract no. OP8]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
98. 98. Combe B, Cosso B, Clot J, et al. Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis. Am J Med 1985; 78: 920-8
99. 99. Sany J, Clot J, Bonneau M, et al. Immunomodulating effect of human placenta-eluted gamma globulins in rheumatoid arthritis. Arthritis Rheum 1982; 25: 17-24
100. 100. Bendtzen K, Hansen MB, Ross C, et al. Cytokines and autoantibodies to cytokines. Stem Cells (Dayt) 1995; 13: 206-22
101. 101. Bendtzen K, Svenson M, Hansen M. Autoantibodies to cytokines m IVIG. J Rheumatol 1993; 20: 2176-7
102. 102. Kondo N, Kasahara K, Kameyama T, et al. Intravenous immunoglobulins suppress immunoglobulin productions be suppressing Ca(2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol 1994; 40: 37-42
103. 103. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91 : 602-7
104. 104. Qi M, Schifferli JA. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum 1995; 38 (1): 146
105. 105. Moynier M, Cosso B, Brochier J, et al. Identification of class II HLA alloantigens in placenta-eluted gammaglobulins used for treating rheumatoid arthritis. Arthritis Rheum 1987; 30: 375-81
106. 106. Nydegger UE, Sultan Y, Kazatchkine MD. The concept of antiidiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol 1989; 53: 72-82
107. 107. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993; 9: 254-62
108. 108. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78: 35-40
109. 109. Zeuner RA, Euler HH, Schroeder JO. High dose intravenous immunoglobulin in autoimmune rheumatic disorders. BioDrugs 1997; 8: 371-86
110. 110. Pratt W, Heck L, Moreland LW, et al. Safety and immunogenicity of single intramuscular injection of a synthetic HLA-DR4/1 peptide vaccine with alum adjuvant in rheumatoid arthritis patients [abstract]. Arthritis Rheum 1995; 38 Suppl.: S281
111. 111. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of auto antigens. Annu Rev Immunol 1994; 12: 809-37
112. 112. Kavanaugh AF, Davis LS, Nichols LA, et al. Retreatment of RA patients with an anti-ICAM-1 monoclonal antibody [abstract]. Arthritis Rheum 1994; 38: S280
113. 113. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with monoclonal antibody to ICAM-1. Arthritis Rheum 1994; 37: 992-9
114. 114. Odell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: result of a double blind placebo controlled trial. Arthritis Rheum 1997; 40: 842-8
115. 115. Emery P. Early rheumatoid arthritis: therapeutic strategies. Scand J Rheumatol Suppl 1994; 100: 3-7
116. 116. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30 (11): 1205-13
117. 117. Silver J, Goyert SM. Epitopes are the functional units of Ia molecules and form the molecular basis for disease susceptibility. In: Ferrone S, Solheim BG, Moller E, editors. Human class II histocompatibility antigens. Berlin: Springer-Verlag, 1985: 32-48
118. 118. Amos RS, Constable TS, Crockson RA, et al. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographie changes. BMJ 1977; 16: 195-7
119. 119. Davis MJ, Dawes PT, Fowler PD, et al. The association and predictive value of the complex immunoglobulin A-alpha 1 antitrypsin in the development of erosions in early rheumatoid arthritis. Scand J Rheumatol 1991; 20: 23-7
120. 120. de Carralno A, Grandal H. Radiographic progression of RA related to some clinical and laboratory parameters. Acta Radiol Diagn (Stockh) 1980; 21: 551-5
121. 121. Lacki JK, Porawska W, Mackiewicz U, et al. Changes in agalactosyl IgG levels correlate with radiological progression in early rheumatoid arthritis. Ann Med 1996; 28: 265-9
122. 122. Lacki JK, Schochat T, Porawska W, et al. Does the serum level of IgA-AT complex correlate with radiological progression of early RA? Rheumatol Int 1995; 14: 227-30
123. 123. Larsen A. The relation of radiographic changes to serum acute phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17: 123-9
124. 124. Scott DL, Coulton BL, Popert AJ. Long-term progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 1986; 45: 373-8
125. 125. Sjoblom KG, Saxne S, Pettersson H, et al. Factors related to the progression of the joint destruction in rheumatoid arthritis. Scand J Rheumatol 1994; 13: 21-7
126. 126. van Zeben D, Breedveld FC. Prognostic factors in rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 31-3
127. 127. van Zeben D, Rook GA, Hazes JM, et al. Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results of a follow-up study. Br J Rheumatol 1994; 33: 36-43
128. 128. Wilske KR, Healey LA. Remodeling the pyramid: concept whose time has come. J Rheumatol 1989; 16: 565-7
129. 129. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the saw-tooth strategy. J Rheumatol 1990; 22 Suppl.: 12-5
130. 130. Wilske KR. Inverting the therapeutic pyramid: observation and recommendation on new directions in rheumatoid arthritis therapy based on the author 's experience. Semin Arthritis Rheum 1993; 23 Suppl. 1: 11-8
131. 131. Asten PM, Barrett JH, Symmons DPM. Rheumatic disease patients treated with immunosuppressants have an increased risk of developing certain types of malignancy compared to the general population [abstract no. 357]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
132. 132. Iannuzzi L, Dawson N, Zein N, et al. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 1983; 309 (17): 1023-8
133. 133. Karateev D, Ivanova M, Akimova T. Death and treatment in patients with rheumatoid arthritis [abstract no. 358]. 14th European Congress of Rheumatology (EULAR); 1999 Jun 6-11; Glasgow
134. 134. Outcome in rheumatoid arthritis. Proceedings of a symposium. Droitwich, Worcestershire, May 8th and 9th, 1987. Br J Rheumatol 1988; 27 Suppl. 1: 1-77
135. 135. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful clinical trials. J Clin Epidemiol 1988; 41: 1037-41
136. 136. Kushner I. Does aggressive therapy of rheumatoid arthritis affect outcome? J Rheumatol 1989; 16: 1-4